Hormonal
Dysfunctional adipose tissue, particularly visceral fat, drives CKM syndrome by secreting proinflammatory and prooxidative products that damage arterial, cardiac, and kidney tissues, leading to insulin resistance and systemic inflammation.
Excess visceral fat is not just stored energy; it actively releases harmful substances that damage your heart, kidneys, and blood vessels. Managing your weight, specifically reducing visceral fat, is a key medical strategy to reduce inflammation and protect your organs.
CKM syndrome most commonly originates from excess or dysfunctional adipose tissue or both. Dysfunctional adipose tissue, particularly visceral adipose tissue, secretes proinflammatory and prooxidative products that damage arterial, cardiac, and kidney tissues.
Why this rating
Supported by extensive literature cited in the AHA scientific statement.
Source
A Synopsis of the Evidence for the Science and Clinical Management of Cardiovascular-Kidney-Metabolic (CKM) Syndrome: A Scientific Statement From the American Heart Association
Chiadi E. Ndumele et al. · Circulation · 2023
DOI 10.1161/cir.0000000000001186
More from this paper
- Cardiovascular-Kidney-Metabolic (CKM) syndrome is a systemic disorder characterized by pathophysiological interactions among metabolic risk factors, chronic kidney disease (CKD), and the cardiovascular system, leading to multiorgan dysfunction and high adverse outcome rates.Strong
- Chronic Kidney Disease (CKD) significantly amplifies cardiovascular risk, with albuminuria and low GFR being strong predictors of major atherosclerotic and heart failure events, often making CVD the leading cause of death in CKD patients.Strong
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →